Inactive Instrument

Press Releases MolMed S.p.A. CBOE EUROPE EQUITIES

Equities

0IE3

IT0001080248

End-of-day quote CBOE EUROPE EQUITIES Other stock markets
- ^EUR	-

2023	Genenta Science S.p.A. and AGC Biologics S.p.A. Enter into A Development and Manufacturing Services Agreement	CI
2022	AGC Biologics and W.L. Gore & Associates Collaborate on New Protein A-Based Purification Technology and Contract Manufacturing Services for Antibody Therapies	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MolMed S p A : CS_ integrativo del Comunicato dimissioni consiglieri	06/08/20	PU
University of Tartu: Novel DNA analysis will help to identify food origin and counterfeit food in the future	08/06/20	AQ
Karolinska Institutet: Overlooked protein could play important part in pneumonia and COVID-19, researchers say	08/05/20	AQ
University of Bristol: UK genome analysis has important implications for COVID-19 clinical trials	02/04/20	AQ
MolMed S p A : KU awards 38 PhD, 16 M. Phil, two Master of Surgery degrees	12/03/20	AQ
MolMed S p A : Karachi University awards 38 MPhil, 16 PhD degrees - Press Release issued by University of Karachi	12/03/20	AQ
MolMed S p A : RhoVac announces appointment of Professor Anne J. Ridley to its Scientific Advisory Board	06/02/20	AQ
MolMed S p A : UCT Shines At L'oréal-Unesco Sub-Saharan Africa	06/12/19	AQ
MolMed S p A : KU awards 34 PhD, 36 MPhil degrees	04/12/19	AQ
MolMed S p A : Karachi University awards 34 PhD, 36 MPhil degrees - Press Release issued by University of Karachi	03/12/19	AQ
MolMed S p A : KU awards PhD, M.Phil and MS Course Work degrees	03/12/19	AQ
MolMed S p A : KU awards 34 PhD, 36 MPhil, 2 MS degrees in various disciplines	03/12/19	AQ
Molecular Medicine : MolMed to present its CDMO services at 2019 CAR-TCR Summit in Boston	12/09/19	PU
Molecular Medicine : MolMed announces the decision to suspend the enrollment of new patients in phase III study TK008 with Zalmoxis®.	27/06/19	PU
Molecular Medicine : MolMed at the 22nd ASGCT congress on continuous innovation in the production of viral vectors for clinical use.	02/05/19	PU
Molecular Medicine : Shareholders meeting approved the Financial Statement 2018. Incerti confirmed Chairman of the BoD and Riccardo Palmisano CEO	30/04/19	PU
Molecular Medicine : MolMed at the “Cell & Gene Meeting on the Med” conference on the opportunities of price and reimbursement in the advanced therapies field	25/04/19	PU
Molecular Medicine : Notice of publication of the Annual Report 2018 and other documents (in Italian) for the Shareholders’ meeting on April 30th, 2019	09/04/19	PU
MolMed: Riccardo Palmisano reappointed representative of small and medium enterprises within the new Executive Council of the Lombardy Life Sciences Cluster.	29/03/19	PU
Molecular Medicine : MolMed received the authorization to start clinical investigation with CAR T CD44v6 cells in AML and MM	20/03/19	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MolMed S.p.A. CBOE EUROPE EQUITIES

Equities

0IE3

IT0001080248

Press Releases

Filters